The Biotech Times

Commercialising the frontiers of biological innovation. Intelligence for pharma, clinical research and life-science investors. A Disrupts Media title.

[The Biotech Times @biotechtimes_]

Pacira out-licenses EXPAREL to Molteni for EU and UK distribution, targeting 2027 commercial launch. Italian pharma gains exclusive rights to the liposomal bupivacaine analgesic. #Pharma #Licensing #EXPAREL

Full story: https://t.co/paliaBV19E

[The Biotech Times @biotechtimes_]

Highlight Therapeutics' BO-112 hit its Phase 2b visual and pathological response endpoint in 61% of basal cell carcinoma patients. Intralesional delivery sidesteps systemic toxicity concerns. #oncology #dermatology #clinicaltrials

Full story: https://t.co/01hWdI3p7R

[The Biotech Times @biotechtimes_]

Novo Nordisk's CagriSema data show weight loss tied to reduced brain food-cue responses and lower ectopic fat, bone density preserved. #obesity #GLP1

Full story: https://t.co/obFPuDiXxM

[The Biotech Times @biotechtimes_]

Boehringer's survodutide cuts weight 13.1% in Phase III obesity-plus-T2D trial, with glycaemic gains in NEJM. Dual GLP-1/GCG agonist advances toward regulatory filing. #obesity #T2D #pharma

Full story: https://t.co/HQmAEJSVne

[The Biotech Times @biotechtimes_]

PolyPid's D-PLEX100 SSI preventative clears EMA validation; FDA PDUFA set for November 2026. #biotech #regulatory

Full story: https://t.co/6NZTONYbqe

[The Biotech Times @biotechtimes_]

Sanofi and Regeneron add four IL-13/IL-4 antibodies to their Dupixent alliance. Regeneron receives $1bn upfront in the $8bn deal. #immunology #biologics

Full story: https://t.co/XQbzjdv5hO

[The Biotech Times @biotechtimes_]

Gates Foundation and Wellcome Leap commit $100m to cut stillbirths through AI diagnostics and biomarker tools, targeting 50% reduction over a decade across select countries. #diagnostics #globalhealth

Full story: https://t.co/NijoLmVHHa

[The Biotech Times @biotechtimes_]

Pharvaris' Phase 3 oral HAE candidate met all 12 endpoints, with symptom relief in 1.28 hours. FDA decision pending. #HAE #pharma

Full story: https://t.co/ci0eWYVCsj

[The Biotech Times @biotechtimes_]

Editas clears regulatory hurdle for EDIT-401 Phase 1/2 trial in Australia. In vivo gene editor targets hyperlipidaemia. #genetherapy #hyperlipidaemia #Editas

Full story: https://t.co/BR1cgbUeco

[The Biotech Times @biotechtimes_]

University of Manchester consortium publishes framework for computer-simulated patients in device regulation. Virtual trials could accelerate regulatory pathways for medical device makers. #medicaldevices #regulatory #biotech

Full story: https://t.co/XLNdSH2y7I

[The Biotech Times @biotechtimes_]

Holobiome and Radicle Science launch 6,000-person gut-brain trial testing 19 prebiotic formulas against anxiety outcomes, with initial results expected in late 2025. #gutbrain #prebiotics #microbiome

Full story: https://t.co/gy1kFxFYxd

[The Biotech Times @biotechtimes_]

Iantrek's bio-reinforced canaloplasty cuts IOP by 37% in early-stage study. Six-month data on 52 eyes, no serious adverse events. #glaucoma #medtech

Full story: https://t.co/zvBgDaFx5M

[The Biotech Times @biotechtimes_]

MMI lands $125m Series D to scale Symani robotic microsurgery. 50 systems installed, 3,500 procedures to date. Full story: #medtech #robotics #surgery https://t.co/07xyWyB9W0

[The Biotech Times @biotechtimes_]

Myriad and SOPHiA GENETICS join forces on a decentralised prostate cancer HRD diagnostic, with AstraZeneca backing the effort. Companion diagnostic play in genomic instability scoring. #diagnostics #prostatecancer #genomics

Full story: https://t.co/xKJZpXDzOd

[The Biotech Times @biotechtimes_]

X4 Pharmaceuticals raises $150m debt to fund mavorixafor Phase 3 and commercial prep. Rare-blood biotech refinances existing facility with K2 HealthVentures. #biotech #rarerare #financing

Full story: https://t.co/af8L95dNAR

[The Biotech Times @biotechtimes_]

iOnctura's roginolisib showed near-threefold OS improvement in metastatic uveal melanoma versus historical controls, with dual Nature Communications papers detailing its novel PI3Kδ binding mechanism. #biotech #oncology

Full story: https://t.co/0MUoCMXGXs

[The Biotech Times @biotechtimes_]

Alumis reports 54% complete skin clearance with envudeucitinib in Phase 3 psoriasis trial. NDA filing planned Q4 2026. #psoriasis #immunology #biotech

Full story: https://t.co/6QZ4vGMWMk

[The Biotech Times @biotechtimes_]

MannKind's Furoscix ReadyFlow shows IV-equivalent diuresis in new PK/PD data. FDA-cleared autoinjector expands outpatient heart failure options. #heartfailure #medtech #furosemide Full story: https://t.co/w92w7DAhrA

[The Biotech Times @biotechtimes_]

Mineralys lorundrostat achieved BP target in 46% of resistant hypertension patients across Launch-HTN and Explore-OSA trials. Data presented at AHA 2026 strengthens the NDA case now under FDA review. #hypertension #cardiology #biotech

Full story: https://t.co/Y8JNnOeXXN

[The Biotech Times @biotechtimes_]

NeuroOne secures $200k from $1m NIH BRAIN grant to co-develop real-time neurotransmitter sensing with Dartmouth. Diagnostic potential in neurological research. #neurotech #NIH #medtech

Full story: https://t.co/8jCazYRagq